Physician profile
Heather D Rowe
NPI 1427066489
$3,771.47
in general payments reported to CMS, 2019-2025
27 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $301 · 2021: $289 · 2022: $291 · 2023: $604 · 2024: $613 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,706 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,706.23 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $927.60 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $625.39 | 2021-2025 | Vraylar, Viberzi, Linzess |
| Astrazeneca Pharmaceuticals LP | $382.91 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $289.44 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $258.09 | 2019-2025 | |
| Astellas Pharma US INC | $204.22 | 2019-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $169.22 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $110.99 | 2019-2025 | Evenity, Prolia, Prolia |
| Novartis Pharmaceuticals Corporation | $105.63 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.55 | 2019-2021 | |
| Alkermes, INC. | $100.66 | 2023 | Aristada, Lybalvi |
| Merck Sharp & Dohme LLC | $88.83 | 2019-2022 | |
| Lilly USA, LLC | $62.53 | 2019-2025 | Mounjaro |
| Radius Health, INC. | $54.23 | 2019-2020 | |
| Bausch Health US, LLC | $40.32 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $36.12 | 2019 | |
| Amarin Pharma, INC. | $25.50 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $25.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.51 | 2021 | |
| Supernus Pharmaceuticals, INC. | $24.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.29 | 2023 | |
| Idorsia Pharmaceuticals US INC | $14.79 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.66 | 2019 | |
| Allergan, INC. | $13.34 | 2020 | |
| Cequr Corporation | $12.66 | 2023 | Cequr Simplicity |
| Sanofi Pasteur INC. | $11.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.